-
Product Insights
Ocular Melanoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Ocular Melanoma - Drugs In Development, 2023’, provides an overview of the Ocular Melanoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Merkel Cell Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Merkel Cell Carcinoma - Drugs In Development, 2023’, provides an overview of the Merkel Cell Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Ultrasound Systems Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Ultrasound Systems Pipeline Market Report Overview Ultrasound Systems are devices that make use of sound waves of high frequency to produce images of structures inside the body. Most of the devices use Sonar principles and are placed outside while in a few cases, they are even placed inside of the body. 2D Ultrasound Systems, 3D Ultrasound Systems, Real-Time 3D Ultrasound Systems, and Hand Held Ultrasound (HHU) Systems are tracked under this category. The Ultrasound Systems pipeline market research report provides...
-
Product Insights
Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) - Drugs In Development, 2023’, provides an overview of the Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers...
-
Product Insights
Nonmelanomatous Skin Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Nonmelanomatous Skin Cancer - Drugs In Development, 2023’, provides an overview of the Nonmelanomatous Skin Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nonmelanomatous Skin Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Sector Analysis
Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Report Overview In 2023, the highest incident cases of Glioblastoma Multiforme (GBM) were from China and India. Glioblastoma Multiforme is a fast-growing and aggressive brain tumor. It is also referred to as a grade IV astrocytoma. GBM invades the nearby brain tissue but generally does not spread to distant organs. There are only a handful of innovator treatment options approved for the treatment of GBM and most conventional marketed drugs are small molecules,...
-
Product Insights
B-Cell Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘B-Cell Leukemia - Drugs In Development, 2023’, provides an overview of the B-Cell Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for B-Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Refractory Chronic Lymphocytic Leukemia (CLL) – Drugs In Development, 2023
Global Markets Direct’s, ‘Refractory Chronic Lymphocytic Leukemia (CLL) - Drugs In Development, 2023’, provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Relapsed Chronic Lymphocytic Leukemia (CLL) – Drugs In Development, 2023
Global Markets Direct’s, ‘Relapsed Chronic Lymphocytic Leukemia (CLL) - Drugs In Development, 2023’, provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Drugs In Development, 2023’, provides an overview of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...